Description

Treatment adherence and dropout rates across curcumin ulcerative colitis trials are comparable between active and placebo groups, indicating good acceptability of curcumin supplementation.

Figure 20

Chart

Source Paper

The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

Nutrients (2020)

PMID: 32751776

DOI: 10.3390/nu12082296

Cite This Figure

![Figure 20: Treatment adherence and dropout rates across curcumin ulcerative colitis trials are comparable between active and placebo groups, indicating good acceptability of curcumin supplementation.]()

> Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." *Nutrients*, 2020. PMID: [32751776](https://pubmed.ncbi.nlm.nih.gov/32751776/)

<figure>
  <img src="" alt="Treatment adherence and dropout rates across curcumin ulcerative colitis trials are comparable between active and placebo groups, indicating good acceptability of curcumin supplementation." />
  <figcaption>Figure 20. Treatment adherence and dropout rates across curcumin ulcerative colitis trials are comparable between active and placebo groups, indicating good acceptability of curcumin supplementation.<br>  Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751776/">32751776</a></figcaption>
</figure>

Related Evidence

Curcumin for Ulcerative Colitis (UC)

Grade B · 5 studies

Curcumin for Crohn's Disease

Grade C · 3 studies